The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | The “controversial situations” seen in FLT3-mutated AML patients
Lars Bullinger
• 25 Oct 2019
Lars Bullinger, MD, Charité University of Medicine, Berlin, Germany, discusses the controversial situations seen in FLT3-mutated acute myeloid leukemia (AML) and the use of the new drug midostaurin. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
